Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence ...
Kyung-Ah Kim, President & CEO of Samsung Bioepis (left) and Zhaoyuan ‘Tony’ Chen, Founder and CEO of Phrontline Biopharma (right) have signed a global strategic partnership agreement to advance ...
LAUSANNE, Switzerland & SUWON-SI GYEONGGI-DO, South Korea--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s ...
Company Expects to Initiate Buildout of Custom Fill-Finish Line in First Quarter of 2026 in Connection with Previously Announced Long-Term Commitment of up to $1 Billion in U.S. Manufacturing and ...
Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents Study initiation follows positive ...
— TAC-001 is the First Candidate from Tallac’s Novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) Platform to Enter the Clinic BURLINGAME, Calif.--(BUSINESS WIRE)-- Tallac Therapeutics, Inc., ...
SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an ...
NaPi2b is a sodium-dependent phosphate transporter that is mainly responsible for phosphate homeostasis in humans. Overexpression of NaPi2b has been associated with several types of cancers such as ...
Epithelial cell adhesion molecule (EpCAM) is involved in cancer cell invasion while it acts as a negative regulator of adhesion. EpCAM is overexpressed in several cancer types, such as colorectal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results